{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:34:00Z","timestamp":1787024040393,"version":"build-2736575974"},"posted":{"date-parts":[[2025,8,19]]},"group-title":"In Review","reference-count":56,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,6,22]]},"abstract":"<title>Abstract<\/title>\n                <p>Fibrotic lung diseases are associated with significant morbidity and mortality, and few therapies have been FDA-approved for patients with these conditions. Therefore, developing effective anti-fibrotic treatments represents an unmet clinical need. Plasminogen activator inhibitor 1 (PAI-1) is an attractive therapeutic target as its expression is up-regulated in the context of fibrotic lung disease, and a causal role for PAI-1 in lung fibrogenesis has been established in complementary animal models. Here, we study the efficacy of a novel small molecule PAI-1 inhibitor, MDI-2517, to attenuate lung fibrosis. We observed that MDI-2517 administered during the fibrotic phase of complementary murine models reduces the severity of scarring. Furthermore, we found that MDI-2517 treatment beginning on day 21 after lung injury accelerates fibrosis resolution while in vitro data reveal that this drug reverses myofibroblast differentiation. These results motivate targeting PAI-1 as a therapy for lung fibrosis and highlight MDI-2517 as a promising drug.<\/p>","DOI":"10.21203\/rs.3.rs-6951289\/v1","type":"posted-content","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T13:34:51Z","timestamp":1755610491000},"source":"Crossref","is-referenced-by-count":2,"title":["Targeting Plasminogen Activator Inhibitor-1 with a Novel Small Molecule Inhibitor Attenuates Lung Fibrosis"],"prefix":"10.21203","author":[{"given":"Thomas H.","family":"Sisson","sequence":"first","affiliation":[{"name":"University of Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Fortier","sequence":"additional","affiliation":[{"name":"University of Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lam C.","family":"Tsoi","sequence":"additional","affiliation":[{"name":"University of Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxann","family":"Alonzo","sequence":"additional","affiliation":[{"name":"University of Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya","family":"Subbotina","sequence":"additional","affiliation":[{"name":"University of Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Warnock","sequence":"additional","affiliation":[{"name":"University of Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Mann","sequence":"additional","affiliation":[{"name":"University of Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey S.","family":"Gutor","sequence":"additional","affiliation":[{"name":"University of Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Craig","family":"Hartman","sequence":"additional","affiliation":[{"name":"University of Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann E.","family":"Gudjonsson","sequence":"additional","affiliation":[{"name":"University of Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enming J.","family":"Su","sequence":"additional","affiliation":[{"name":"University of Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory D.","family":"Emal","sequence":"additional","affiliation":[{"name":"Eastern Michigan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Lawrence","sequence":"additional","affiliation":[{"name":"University of Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic Pulmonary Fibrosis","volume":"378","author":"Lederer DJ","year":"2018","unstructured":"Lederer, D. J. & Martinez, F. J. Idiopathic Pulmonary Fibrosis. N Engl J Med 378, 1811\u20131823 (2018). https:\/\/doi.org:10.1056\/NEJMra1705751","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01158-9","article-title":"Fibrosis: cross-organ biology and pathways to development of innovative drugs","author":"Rieder F","year":"2025","unstructured":"Rieder, F. et al. Fibrosis: cross-organ biology and pathways to development of innovative drugs. Nat Rev Drug Discov (2025). https:\/\/doi.org:10.1038\/s41573-025-01158-9","journal-title":"Nat Rev Drug Discov"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"Flaherty KR","year":"2019","unstructured":"Flaherty, K. R. et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 381, 1718\u20131727 (2019). https:\/\/doi.org:10.1056\/NEJMoa1908681","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi L","year":"2014","unstructured":"Richeldi, L. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370, 2071\u20132082 (2014). https:\/\/doi.org:10.1056\/NEJMoa1402584","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","article-title":"Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"171","author":"Azuma A","year":"2005","unstructured":"Azuma, A. et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171, 1040\u20131047 (2005). https:\/\/doi.org:10.1164\/rccm.200404-571OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2174\/138945007781662337","article-title":"Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent","volume":"8","author":"Cale JM","year":"2007","unstructured":"Cale, J. M. & Lawrence, D. A. Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent. Curr Drug Targets 8, 971\u2013981 (2007). https:\/\/doi.org:10.2174\/138945007781662337","journal-title":"Curr Drug Targets"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1055\/s-0042-1758791","article-title":"Present, and Future Perspectives of Plasminogen Activator Inhibitor 1 (PAI-1)","volume":"49","author":"Morrow GB","year":"2023","unstructured":"Morrow, G. B. & Mutch, N. J. Past, Present, and Future Perspectives of Plasminogen Activator Inhibitor 1 (PAI-1). Semin Thromb Hemost 49, 305\u2013313 (2023). https:\/\/doi.org:10.1055\/s-0042-1758791","journal-title":"Semin Thromb Hemost"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"6358","DOI":"10.1074\/jbc.273.11.6358","article-title":"Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein","volume":"273","author":"Stefansson S","year":"1998","unstructured":"Stefansson, S. et al. Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein. J Biol Chem 273, 6358\u20136366 (1998). https:\/\/doi.org:10.1074\/jbc.273.11.6358","journal-title":"J Biol Chem"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1161\/ATVBAHA.114.304554","article-title":"Plasminogen activator inhibitor-1 inhibits angiogenic signaling by uncoupling vascular endothelial growth factor receptor-2-alphaVbeta3 integrin cross talk","volume":"35","author":"Wu J","year":"2015","unstructured":"Wu, J. et al. Plasminogen activator inhibitor-1 inhibits angiogenic signaling by uncoupling vascular endothelial growth factor receptor-2-alphaVbeta3 integrin cross talk. Arterioscler Thromb Vasc Biol 35, 111\u2013120 (2015). https:\/\/doi.org:10.1161\/ATVBAHA.114.304554","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1042\/BJ20040149","article-title":"The mosaic receptor sorLA\/LR11 binds components of the plasminogen-activating system and platelet-derived growth factor-BB similarly to LRP1 (low-density lipoprotein receptor-related protein), but mediates slow internalization of bound ligand","volume":"381","author":"Gliemann J","year":"2004","unstructured":"Gliemann, J. et al. The mosaic receptor sorLA\/LR11 binds components of the plasminogen-activating system and platelet-derived growth factor-BB similarly to LRP1 (low-density lipoprotein receptor-related protein), but mediates slow internalization of bound ligand. Biochem J 381, 203\u2013212 (2004). https:\/\/doi.org:10.1042\/BJ20040149","journal-title":"Biochem J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.186131","article-title":"PAI-1 Interaction with Sortilin Related Receptor-1 is Required for Lung Fibrosis","author":"Sisson TH","year":"2025","unstructured":"Sisson, T. H. et al. PAI-1 Interaction with Sortilin Related Receptor-1 is Required for Lung Fibrosis. JCI Insight (2025). https:\/\/doi.org:10.1172\/jci.insight.186131","journal-title":"JCI Insight"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1172\/JCI118396","article-title":"Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene","volume":"97","author":"Eitzman DT","year":"1996","unstructured":"Eitzman, D. T. et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97, 232\u2013237 (1996). https:\/\/doi.org:10.1172\/JCI118396","journal-title":"J Clin Invest"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1172\/JCI10531","article-title":"Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice","volume":"106","author":"Hattori N","year":"2000","unstructured":"Hattori, N. et al. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 106, 1341\u20131350 (2000). https:\/\/doi.org:10.1172\/JCI10531","journal-title":"J Clin Invest"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1136\/thx.2009.119974","article-title":"Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis","volume":"65","author":"Senoo T","year":"2010","unstructured":"Senoo, T. et al. Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax 65, 334\u2013340 (2010). https:\/\/doi.org:10.1136\/thx.2009.119974","journal-title":"Thorax"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1182\/blood-2010-12-324574","article-title":"The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice","volume":"118","author":"Courey AJ","year":"2011","unstructured":"Courey, A. J. et al. The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice. Blood 118, 2313\u20132321 (2011). https:\/\/doi.org:10.1182\/blood-2010-12-324574","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/path.3992","article-title":"PAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury","volume":"228","author":"Osterholzer JJ","year":"2012","unstructured":"Osterholzer, J. J. et al. PAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury. J Pathol 228, 170\u2013180 (2012). https:\/\/doi.org:10.1002\/path.3992","journal-title":"J Pathol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"L344-357","DOI":"10.1152\/ajplung.00300.2014","article-title":"Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis","volume":"308","author":"Liu F","year":"2015","unstructured":"Liu, F. et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am J Physiol Lung Cell Mol Physiol 308, L344-357 (2015). https:\/\/doi.org:10.1152\/ajplung.00300.2014","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e0148969","DOI":"10.1371\/journal.pone.0148969","article-title":"Inhibition of Plasminogen Activator Inhibitor-1 Attenuates Transforming Growth Factor-beta-Dependent Epithelial Mesenchymal Transition and Differentiation of Fibroblasts to Myofibroblasts","volume":"11","author":"Omori K","year":"2016","unstructured":"Omori, K. et al. Inhibition of Plasminogen Activator Inhibitor-1 Attenuates Transforming Growth Factor-beta-Dependent Epithelial Mesenchymal Transition and Differentiation of Fibroblasts to Myofibroblasts. PLoS One 11, e0148969 (2016). https:\/\/doi.org:10.1371\/journal.pone.0148969","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1165\/rcmb.2019-0071OC","article-title":"PAI-1 Regulation of TGF-beta1-induced Alveolar Type II Cell Senescence, SASP Secretion, and SASP-mediated Activation of Alveolar Macrophages","volume":"62","author":"Rana T","year":"2020","unstructured":"Rana, T. et al. PAI-1 Regulation of TGF-beta1-induced Alveolar Type II Cell Senescence, SASP Secretion, and SASP-mediated Activation of Alveolar Macrophages. Am J Respir Cell Mol Biol 62, 319\u2013330 (2020). https:\/\/doi.org:10.1165\/rcmb.2019-0071OC","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/B978-0-12-385950-1.00009-2","article-title":"Development of inhibitors of plasminogen activator inhibitor-1","volume":"501","author":"Li SH","year":"2011","unstructured":"Li, S. H. & Lawrence, D. A. Development of inhibitors of plasminogen activator inhibitor-1. Methods Enzymol 501, 177\u2013207 (2011). https:\/\/doi.org:10.1016\/B978-0-12-385950-1.00009-2","journal-title":"Methods Enzymol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1517\/13543776.2013.782393","article-title":"Plasminogen activator inhibitor-1 inhibitors: a patent review (2006-present)","volume":"23","author":"Fortenberry YM","year":"2013","unstructured":"Fortenberry, Y. M. Plasminogen activator inhibitor-1 inhibitors: a patent review (2006-present). Expert Opin Ther Pat 23, 801\u2013815 (2013). https:\/\/doi.org:10.1517\/13543776.2013.782393","journal-title":"Expert Opin Ther Pat"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ejmech.2015.01.010","article-title":"Small molecules inhibitors of plasminogen activator inhibitor-1 - an overview","volume":"92","author":"Rouch A","year":"2015","unstructured":"Rouch, A., Vanucci-Bacque, C., Bedos-Belval, F. & Baltas, M. Small molecules inhibitors of plasminogen activator inhibitor-1 - an overview. Eur J Med Chem 92, 619\u2013636 (2015). https:\/\/doi.org:10.1016\/j.ejmech.2015.01.010","journal-title":"Eur J Med Chem"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1172\/JCI117937","article-title":"Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro","volume":"95","author":"Eitzman DT","year":"1995","unstructured":"Eitzman, D. T. et al. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest 95, 2416\u20132420 (1995). https:\/\/doi.org:10.1172\/JCI117937","journal-title":"J Clin Invest"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"18147","DOI":"10.1074\/jbc.M709455200","article-title":"Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands","volume":"283","author":"Li SH","year":"2008","unstructured":"Li, S. H., Gorlatova, N. V., Lawrence, D. A. & Schwartz, B. S. Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands. J Biol Chem 283, 18147\u201318157 (2008). https:\/\/doi.org:10.1074\/jbc.M709455200","journal-title":"J Biol Chem"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1161\/ATVBAHA.107.157479","article-title":"Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis","volume":"28","author":"Izuhara Y","year":"2008","unstructured":"Izuhara, Y. et al. Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis. Arterioscler Thromb Vasc Biol 28, 672\u2013677 (2008). https:\/\/doi.org:10.1161\/ATVBAHA.107.157479","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.tips.2021.03.006","article-title":"Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19","volume":"42","author":"Kellici TF","year":"2021","unstructured":"Kellici, T. F., Pilka, E. S. & Bodkin, M. J. Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19. Trends Pharmacol Sci 42, 431\u2013433 (2021). https:\/\/doi.org:10.1016\/j.tips.2021.03.006","journal-title":"Trends Pharmacol Sci"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1002\/cam4.5292","article-title":"Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor","volume":"12","author":"Takahashi N","year":"2023","unstructured":"Takahashi, N. et al. Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor. Cancer Med 12, 4250\u20134258 (2023). https:\/\/doi.org:10.1002\/cam4.5292","journal-title":"Cancer Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41598-023-50445-1","article-title":"A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19","volume":"14","author":"Hirai T","year":"2024","unstructured":"Hirai, T. et al. A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19. Sci Rep 14, 165 (2024). https:\/\/doi.org:10.1038\/s41598-023-50445-1","journal-title":"Sci Rep"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1021\/jm049766q","article-title":"Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization","volume":"47","author":"Elokdah H","year":"2004","unstructured":"Elokdah, H. et al. Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. J Med Chem 47, 3491\u20133494 (2004). https:\/\/doi.org:10.1021\/jm049766q","journal-title":"J Med Chem"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"9288","DOI":"10.1074\/jbc.M611642200","article-title":"Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor","volume":"282","author":"Gorlatova NV","year":"2007","unstructured":"Gorlatova, N. V. et al. Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor. J Biol Chem 282, 9288\u20139296 (2007). https:\/\/doi.org:10.1074\/jbc.M611642200","journal-title":"J Biol Chem"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1165\/rcmb.2011-0139OC","article-title":"Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis","volume":"46","author":"Huang WT","year":"2012","unstructured":"Huang, W. T., Vayalil, P. K., Miyata, T., Hagood, J. & Liu, R. M. Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis. Am J Respir Cell Mol Biol 46, 87\u201395 (2012). https:\/\/doi.org:10.1165\/rcmb.2011-0139OC","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"16329","DOI":"10.1074\/jbc.M208420200","article-title":"Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis. Implications for serpin function","volume":"278","author":"Gorlatova NV","year":"2003","unstructured":"Gorlatova, N. V., Elokdah, H., Fan, K., Crandall, D. L. & Lawrence, D. A. Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis. Implications for serpin function. J Biol Chem 278, 16329\u201316335 (2003). https:\/\/doi.org:10.1074\/jbc.M208420200","journal-title":"J Biol Chem"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/355270a0","article-title":"Structural basis of latency in plasminogen activator inhibitor-1","volume":"355","author":"Mottonen J","year":"1992","unstructured":"Mottonen, J. et al. Structural basis of latency in plasminogen activator inhibitor-1. Nature 355, 270\u2013273 (1992). https:\/\/doi.org:10.1038\/355270a0","journal-title":"Nature"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1074\/jbc.RA118.004885","article-title":"Dual-reporter high-throughput screen for small-molecule in vivo inhibitors of plasminogen activator inhibitor type-1 yields a clinical lead candidate","volume":"294","author":"Reinke AA","year":"2019","unstructured":"Reinke, A. A. et al. Dual-reporter high-throughput screen for small-molecule in vivo inhibitors of plasminogen activator inhibitor type-1 yields a clinical lead candidate. J Biol Chem 294, 1464\u20131477 (2019). https:\/\/doi.org:10.1074\/jbc.RA118.004885","journal-title":"J Biol Chem"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat0852","article-title":"PAI-1 augments mucosal damage in colitis","volume":"11","author":"Kaiko GE","year":"2019","unstructured":"Kaiko, G. E. et al. PAI-1 augments mucosal damage in colitis. Sci Transl Med 11 (2019). https:\/\/doi.org:10.1126\/scitranslmed.aat0852","journal-title":"Sci Transl Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1161\/ATVBAHA.119.313775","article-title":"Drug Targeting of Plasminogen Activator Inhibitor-1 Inhibits Metabolic Dysfunction and Atherosclerosis in a Murine Model of Metabolic Syndrome","volume":"40","author":"Khoukaz HB","year":"2020","unstructured":"Khoukaz, H. B. et al. Drug Targeting of Plasminogen Activator Inhibitor-1 Inhibits Metabolic Dysfunction and Atherosclerosis in a Murine Model of Metabolic Syndrome. Arterioscler Thromb Vasc Biol 40, 1479\u20131490 (2020). https:\/\/doi.org:10.1161\/ATVBAHA.119.313775","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s12975-022-00992-y","article-title":"Compartmentalized Actions of the Plasminogen Activator Inhibitors, PAI-1 and Nsp, in Ischemic Stroke","volume":"13","author":"Torrente D","year":"2022","unstructured":"Torrente, D. et al. Compartmentalized Actions of the Plasminogen Activator Inhibitors, PAI-1 and Nsp, in Ischemic Stroke. Transl Stroke Res 13, 801\u2013815 (2022). https:\/\/doi.org:10.1007\/s12975-022-00992-y","journal-title":"Transl Stroke Res"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1164\/rccm.200810-1615OC","article-title":"Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis","volume":"181","author":"Sisson TH","year":"2010","unstructured":"Sisson, T. H. et al. Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med 181, 254\u2013263 (2010). https:\/\/doi.org:10.1164\/rccm.200810-1615OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin A","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013). https:\/\/doi.org:10.1093\/bioinformatics\/bts635","journal-title":"Bioinformatics"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq\u2013a Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders S","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq\u2013a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015). https:\/\/doi.org:10.1093\/bioinformatics\/btu638","journal-title":"Bioinformatics"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love MI","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550 (2014). https:\/\/doi.org:10.1186\/s13059-014-0550-8","journal-title":"Genome Biol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1136\/annrheumdis-2015-eular.5282","article-title":"Distler. Biomarkers Sensitive to Change in Patients with Systemic Sclerosis \u2013 a Systematic Review","volume":"74","author":"Toniolo M","year":"2015","unstructured":"M. Toniolo, R. D., P. Moinzadeh, R. Ogawa, D.E. Furst, C.P. Denton, D. Khanna, O. Distler. Biomarkers Sensitive to Change in Patients with Systemic Sclerosis \u2013 a Systematic Review. Annals of the Rheumatic Diseases 74, 1140 (2015). https:\/\/doi.org:10.1136\/annrheumdis-2015-eular.5282","journal-title":"Annals of the Rheumatic Diseases"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1165\/rcmb.2015-0020TR","article-title":"Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis","volume":"53","author":"Craig VJ","year":"2015","unstructured":"Craig, V. J., Zhang, L., Hagood, J. S. & Owen, C. A. Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 53, 585\u2013600 (2015). https:\/\/doi.org:10.1165\/rcmb.2015-0020TR","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25168946","article-title":"Cellular and Molecular Genetic Mechanisms of Lung Fibrosis Development and the Role of Vitamin D: A Review","volume":"25","author":"Enzel D","year":"2024","unstructured":"Enzel, D., Kriventsov, M., Sataieva, T. & Malygina, V. Cellular and Molecular Genetic Mechanisms of Lung Fibrosis Development and the Role of Vitamin D: A Review. Int J Mol Sci 25 (2024). https:\/\/doi.org:10.3390\/ijms25168946","journal-title":"Int J Mol Sci"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1032355","DOI":"10.3389\/fimmu.2023.1032355","article-title":"Potential targeted therapy based on deep insight into the relationship between the pulmonary microbiota and immune regulation in lung fibrosis","volume":"14","author":"Zhang T","year":"2023","unstructured":"Zhang, T., Zhang, M., Yang, L., Gao, L. & Sun, W. Potential targeted therapy based on deep insight into the relationship between the pulmonary microbiota and immune regulation in lung fibrosis. Front Immunol 14, 1032355 (2023). https:\/\/doi.org:10.3389\/fimmu.2023.1032355","journal-title":"Front Immunol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"231ra247","DOI":"10.1126\/scitranslmed.3008182","article-title":"Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance","volume":"6","author":"Hecker L","year":"2014","unstructured":"Hecker, L. et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci Transl Med 6, 231ra247 (2014). https:\/\/doi.org:10.1126\/scitranslmed.3008182","journal-title":"Sci Transl Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/jcp.22783","article-title":"PAI-1 in tissue fibrosis","volume":"227","author":"Ghosh AK","year":"2012","unstructured":"Ghosh, A. K. & Vaughan, D. E. PAI-1 in tissue fibrosis. J Cell Physiol 227, 493\u2013507 (2012). https:\/\/doi.org:10.1002\/jcp.22783","journal-title":"J Cell Physiol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2414108","article-title":"Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis","author":"Richeldi L","year":"2025","unstructured":"Richeldi, L. et al. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med (2025). https:\/\/doi.org:10.1056\/NEJMoa2414108","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.tins.2020.08.003","article-title":"VPS10P Domain Receptors: Sorting Out Brain Health and Disease","volume":"43","author":"Malik AR","year":"2020","unstructured":"Malik, A. R. & Willnow, T. E. VPS10P Domain Receptors: Sorting Out Brain Health and Disease. Trends Neurosci 43, 870\u2013885 (2020). https:\/\/doi.org:10.1016\/j.tins.2020.08.003","journal-title":"Trends Neurosci"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13024-022-00576-2","article-title":"Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer's disease","volume":"17","author":"Salasova A","year":"2022","unstructured":"Salasova, A., Monti, G., Andersen, O. M. & Nykjaer, A. Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer's disease. Mol Neurodegener 17, 74 (2022). https:\/\/doi.org:10.1186\/s13024-022-00576-2","journal-title":"Mol Neurodegener"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1006\/abio.1994.1042","article-title":"An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct","volume":"216","author":"Abe M","year":"1994","unstructured":"Abe, M. et al. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 216, 276\u2013284 (1994). https:\/\/doi.org:10.1006\/abio.1994.1042","journal-title":"Anal Biochem"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/j.1460-2075.1987.tb02365.x","article-title":"Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts","volume":"6","author":"Lund LR","year":"1987","unstructured":"Lund, L. R. et al. Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J 6, 1281\u20131286 (1987). https:\/\/doi.org:10.1002\/j.1460-2075.1987.tb02365.x","journal-title":"EMBO J"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1093\/emboj\/17.11.3091","article-title":"Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene","volume":"17","author":"Dennler S","year":"1998","unstructured":"Dennler, S. et al. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17, 3091\u20133100 (1998). https:\/\/doi.org:10.1093\/emboj\/17.11.3091","journal-title":"EMBO J"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.cellsig.2012.10.003","article-title":"TGF-beta signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities","volume":"25","author":"Samarakoon R","year":"2013","unstructured":"Samarakoon, R., Overstreet, J. M. & Higgins, P. J. TGF-beta signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities. Cell Signal 25, 264\u2013268 (2013). https:\/\/doi.org:10.1016\/j.cellsig.2012.10.003","journal-title":"Cell Signal"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jcb.26146","article-title":"Plasminogen Activator Inhibitor Type-1 as a Regulator of Fibrosis","volume":"119","author":"Rabieian R","year":"2018","unstructured":"Rabieian, R. et al. Plasminogen Activator Inhibitor Type-1 as a Regulator of Fibrosis. J Cell Biochem 119, 17\u201327 (2018). https:\/\/doi.org:10.1002\/jcb.26146","journal-title":"J Cell Biochem"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1111\/j.1440-1746.2008.05485.x","article-title":"Inhibition of plasminogen activator inhibitor-1 expression by siRNA in rat hepatic stellate cells","volume":"23","author":"Hu PF","year":"2008","unstructured":"Hu, P. F. et al. Inhibition of plasminogen activator inhibitor-1 expression by siRNA in rat hepatic stellate cells. J Gastroenterol Hepatol 23, 1917\u20131925 (2008). https:\/\/doi.org:10.1111\/j.1440-1746.2008.05485.x","journal-title":"J Gastroenterol Hepatol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6951289\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6951289\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T13:34:57Z","timestamp":1755610497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6951289\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":56,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-6951289\/v1","relation":{},"subject":[],"published":{"date-parts":[[2025,8,19]]},"subtype":"preprint"}}